Physician profile
Qin Gu
NPI 1487691507
$11,380.05
in general payments reported to CMS, 2019-2025
53 companies · $2,557 in 2025
The $2,557 reported for 2025 was more than what 77% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $926 · 2020: $1,185 · 2021: $1,802 · 2022: $1,731 · 2023: $1,644 · 2024: $1,536 · 2025: $2,557.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,737.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,737.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $945.58 | 2019-2025 | |
| Biogen, INC. | $767.52 | 2019-2025 | Vumerity, Tysabri, Avonex |
| Teva Pharmaceuticals USA, INC. | $737.86 | 2020-2025 | Austedo Xr, Austedo Xr, Austedo |
| Abbvie INC. | $706.55 | 2021-2025 | |
| Ucb, INC. | $695.67 | 2019-2025 | Rystiggo, Briviact, Nayzilam |
| Pfizer INC. | $657.13 | 2023-2025 | |
| Eisai INC. | $646.40 | 2020-2025 | |
| Neurocrine Biosciences, INC. | $545.76 | 2020-2025 | Ingrezza, Ongentys |
| Amgen INC. | $443.23 | 2019-2025 | Uplizna |
| Jazz Pharmaceuticals INC. | $395.36 | 2022-2024 | |
| Sunovion Pharmaceuticals INC. | $375.46 | 2019-2022 | |
| Genentech USA, INC. | $348.36 | 2019-2025 | Ocrevus, Ocrevus Zunovo |
| Lundbeck LLC | $316.64 | 2019-2025 | Vyepti |
| Supernus Pharmaceuticals, INC. | $314.35 | 2019-2021 | |
| Emd Serono, INC. | $308.40 | 2019-2022 |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Qin Gu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.